Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07016412 · ClinicalTrials.gov registry record · Phase 2
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD
A Phase 2 study of Chronic Obstructive Pulmonary Disease, sponsored by Verona Pharma.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 480
- Enrollment target
- 20
- Study locations
NCT07016412 is a Phase 2 study of Chronic Obstructive Pulmonary Disease that is actively recruiting participants, run by Verona Pharma. The registered enrollment target is 480 participants, below the 1,748-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT07016412, a Phase 2 study of Chronic Obstructive Pulmonary Disease, is actively recruiting participants, sponsored by Verona Pharma.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 480 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the safety and efficacy of fixed dose combinations of ensifentrine with two different glycopyrrolate dose levels compared to placebo and to the individual components of the fixed dose combinations, each administered twice a day via standard jet nebulizer, in adult subjects with chronic obstructive pulmonary disease (COPD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ensifentrine 3 mg
- DRUG Glycopyrrolate 21.25 mcg
- DRUG Glycopyrrolate 42.5 mcg
Study Locations (20)
Florida
- Clinical Research of West Florida Inc - Clearwater
- Fleming Island Center For Clinical Research - Fleming Island
- Florida Institute For Clinical Research LLC - Orlando
- Ormond Beach Clinical Research - Ormond Beach
- Progressive Medical Research - Port Orange
- Clinical Research of West Florida Inc - Tampa - Tampa
California
- Downtown LA Research Center Inc - ClinEdge - Los Angeles
- California Medical Research Associates, Inc. - Northridge
- Northern California Research Corp - Sacramento
Missouri
- Midwest Chest Consultants PC - Saint Charles
- Midwest Clinical Research LLC - St Louis
- The Clinical Research Center LLC - CRN - St Louis
Georgia
- Centricity Research Columbus Georgia - Columbus
- Southeast Lung Associates Research - Rincon
Indiana
- ASHA Clinical Research - Hammond - Hammond
- Velocity Clinical Research - Valparaiso - Valparaiso
Alabama
- SEC Clinical Research, LLC - Dothan
Arizona
- Elite Clinical Studies, LLC - Phoenix
Maryland
- Velocity Clinical Research - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2025-07-31 |
| Est. Completion | 2026-04-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07016412
The ClinicalTrials.gov registry entry for NCT07016412 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 480 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,748-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (73% lower). The listed sponsor is Verona Pharma, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT07016412 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Missouri.
Frequently Asked Questions
What is clinical trial NCT07016412 about?
NCT07016412 is a clinical study titled "A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD". This study will assess the safety and efficacy of fixed dose combinations of ensifentrine with two different glycopyrrolate dose levels compared to placebo and to the individual components of the fixed dose combinations, each administered twice a day via standard jet nebulizer, in adult subjects wit...
What is the current status of trial NCT07016412?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 480 participants. The study started on 2025-07-31. Estimated completion is 2026-04-29.
What conditions does trial NCT07016412 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease.
What interventions are being tested in trial NCT07016412?
The interventions under investigation include: Placebo (DRUG), Ensifentrine 3 mg (DRUG), Glycopyrrolate 21.25 mcg (DRUG), Glycopyrrolate 42.5 mcg (DRUG).
Who is sponsoring clinical trial NCT07016412?
This trial is sponsored by Verona Pharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07016412 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
RECRUITING · Phase 2
-
The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)
RECRUITING · Phase 2
-
Biological Effects of Quercetin in COPD Phase II
RECRUITING · Phase 2
-
Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
RECRUITING · Phase 2
-
Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD
RECRUITING · Phase 2
-
A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.